Cellular Senescence in COPD
Can targeting cellular senescence in the airways improve COPD outcomes?
Following this question connects research on airway ageing with investigations of pulmonary rehabilitation and metformin, helping readers assess whether proposed mechanisms translate into measurable benefits.
Where it stands now
Main bottleneck
Establishing whether changing cellular senescence improves COPD outcomes. The supplied trajectory identifies mechanistic research and a trial entry but provides no results establishing clinical benefit or safety.
Watch next
Results from the listed investigation showing whether pulmonary rehabilitation or metformin changes measures of senescence alongside COPD outcomes, including exacerbations, with safety findings.
Progress timeline
How the evidence has changed over time.
2025 · 1 update
- What researchers plan to learn from six months of metformin in people with chronic obstructive pulmonary disease who do not have diabetesResearch note 3 of 3 · Source date 2025-12-10
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: Removing harmful airway cells or changing their activity
Previous expectation: Safely controlling harmful airway-cell states might preserve airway repair and help protect lung function in people with COPD.
What this study adds: The supplied registry record describes a concrete plan to investigate metformin safety, tolerability and aging-associated blood markers in people with COPD without diabetes. It supplies no patient findings that test the earlier selective-cell-control forecast.
Current research note
2023 · 1 update
- Removing harmful airway cells or changing their activityResearch note 2 of 3 · Source date 2023-07-23
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: How stalled cell renewal may sustain chronic lung injury
Previous expectation: Safely targeting persistent damaging cell states might preserve lung function by reducing injury and protecting repair.
What this study adds: The July 2023 review gives that therapeutic direction greater airway-epithelial specificity, connecting damage responses and impaired mitochondrial clearance with inflammatory secretion and describing pathway intervention in COPD epithelial cells. It does not test the earlier forecast of durable patient benefit.
Current research note
2022 · 1 update
- How stalled cell renewal may sustain chronic lung injuryResearch note 1 of 3 · Source date 2022-06-17
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.